The COPD study at the University of Vienna Hospital and published in CHEST (2005) is one such good piece of research despite what minor critique has been given to it. Although some weak critique was made about the treatment group and the control group were not perfectly comparable, there was not statistical difference between the groups, and due to the substantial differences in treatment results, this trial fits your criteria...but heck, you can never admit you're wrong, so what is the point?
Unless someone can provide a statistical analysis of why the results of this trial are not valid, please just admit that there are good reasons that CHEST published this fine piece of research...and if you and someone in your family had COPD, would you consider using the homeopathic medicine that was shown to be helpful? What is interesting and unusual about THIS study was that only ONE homeopathic medicine was given, without individualization of treatment. The results of this trial surprised me, but this medicine is known to cause (and cure) thick tracheal secretions like those with advanced COPD.
My previous reference to another trial also at the University of Vienna Hospital on patients with severe sepsis found a 50% reduced mortality rate in patients who were given an individually selected homeopathic medicine, as compared with those given a placebo. The only critique that was given to this trial was that people should avoid Vienna is the normal death rate for severe sepsis is 50%, even though the literature normally find that the death rate for this serious condition is between 40-70% (is this condition adequately beyond self-limiting?).
That said...there is so much more (but those of you who don't look will never find anything).
A small but significant study of people with brain cancer was conducted in association with M.D. Anderson Cancer Center at the University of Texas (one of the most respected cancer research centers in the world), and it was published in the prestigious journal, International Journal of Oncology). Fifteen patient diagnosed with intracranial tumors were treated with Ruta 6X and Calcarea phosphorica (calcium phosphate) 3X (Pathak, Multani, Banerji, 2003). Of the 15 patients, 8 of the 9 glioma patients showed complete regression of tumors; 1 of 3 with meningioma showed complete regression and 2 of 3 showed prolonged arrest; 1 with neurinoma showed prolonged arrest; 1 with craiopharyngioma and 1 with pituitary tumors both showed complete regression.
Providing further verification of the benefits of Ruta graveolens was an animal study (Preethi K, Kuttan G, Kuttan, 2006). An extract of Ruta graveolens was found to be cytotoxic to Dalton's lymphoma ascites (DLA), Ehrlich ascites carcinoma (EAC) and L929 cells in culture (IC100 = 16mg/ml) and also to increase the lifespan of tumour bearing animals. The extract further decreased solid tumours developing from DLA and EAC cells when given simultaneously with elongation of the lifespan of tumour-bearing animals. A homeopathic preparation of Ruta graveolens (200c) was equally effective. Neither was effective for reducing already developed tumours. The Ruta graveolens extract was found to scavenge hydroxyl radicals and inhibit lipid peroxidation at low concentrations. However, at higher concentrations the extract acted as a prooxidant as inhibition of lipid peroxidation and scavenging of hydroxyl radical was minimal. These data indicates that the prooxidant activity of Ruta graveolens may be responsible for the cytocidal action of the extract and its ability to produce tumour reduction.
These researchers also conducted several laboratory experiments in which one or both of these homeopathic medicines showed induction of survival-signaling pathways in normal lymphocytes as well as the induction of death-signaling pathways in brain cancer cells (this means that these medicines improved immune function and increased the body’s ability to kill cancer cells). The researchers also note that one of Ruta’s active ingredients is Rutin, which is know for having anti-oxidant and anti-inflammatory activities and for reducing oxidative damage. The researchers also provide additional detail about the therapeutic benefits from calcium phosphate.
Pathak S, Multani AS, Banerji P, Banerji P., Ruta 6 selectively induces cell death in brain cancer cells but proliferation in normal peripheral blood lymphocytes: A novel treatment for human brain cancer. Int J Oncol. 2003 Oct;23(4):975-82.
Preethi K, Kuttan G, Kuttan R Anti-tumour activity of ruta graveolens extract. Asian Pac J Cancer Prev. 2006 Jul-Sep;7(3):439-43.